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Infection of resting peripheral mononuclear blood cells (PBMCs) with HIV-1 is not productive due to a block prior to integration of the
provirus into the host genome. Here we show that a unique restriction is determined by the status of the glucocorticoid receptor (GR). Proviral
integration increases after addition of a GR ligand. The ligand dependent effect is confined to an early time period after infection and requires GR
and the GR binding viral protein Vpr. Endogenous GR and transiently expressed Vpr are localized in the cytoplasm in unstimulated PMCs and
comigrate into the nucleus upon ligand addition. Thus, the predominant cytoplasmic localization of GR seems to be a specific obstacle for HIV
replication. Accordingly, efficient proviral integration in a cell line with a constitutive cytoplasmic GR requires addition of a GR ligand. The data
suggest that steroids can overcome the restriction on HIV provirus formation and thereby increase the reservoir of virus producing cells.
© 2008 Elsevier Inc. All rights reserved.Keywords: HIV; PBMCs; Glucocorticoid receptor; Dexamethasone; Preintegration complex; Vpr; Provirus; Gag; Rat glioma cellsIntroduction
The role of HIV receptors and coreceptors, the mechanisms
leading to fusion of viral and host cell membranes, and the
subsequent entry of the viral cores have been elucidated at the
molecular level, leading already to new therapeutic approaches
to prevent infection (reviewed in: Moore and Stevenson, 2000;
Ray and Doms, 2006). However, the steps occurring after entry
are still poorly understood. It remains particularly unclear which
cellular factors influence the early steps of a viral infection.
Unlike beta- and gamma-retroviruses which require cell
division to allow effective infection, lentiviruses can also infect
resting cells, although with lower efficiency. Several studies
have shown that HIV is restricted at the post-entry stage in
resting T cells and in freshly isolated PBMCs in vitro (Zack
et al., 1990; Stevenson et al., 1990). After stimulation of
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(Pomerantz et al., 1990; Rosenberg and Fauci, 1990). The
factors that restrict HIV-1 replication in unstimulated mono-
nuclear cells are not yet clearly defined. For resting T cells it
was shown that the block likely exists after reverse transcription
and prior to integration of the viral genome into the host
genome. It was suggested that these cells do not to allow
complete reverse transcription and the viral DNA stays in a
transcriptionally nonfunctional form (Blaak et al., 2000; Sonza
et al., 1996; Stevenson et al., 1990).
A number of cellular proteins have been implicated in the
early block to infection. For example, it was shown that the
cytidine deaminase APOBEC3G could cause high levels of
hypermutations in theHIV genome (Bishop et al., 2004;Mangeat
et al., 2003; Sheehy et al., 2002). The effect is counteracted by the
viral protein Vif which causes proteosomal degradation of
APOBEC3G (Sheehy et al., 2003). But APOBEC3G causes an
additional severe defect at the level of reverse transcription,
which is independent of its deaminase activity (Chiu et al., 2005).
In nonpermissive cells APOBEC3G resided in a low-molecular-
mass (LMM) complex which is converted into a high-molecular-
mass (HMM) complex in permissive cells upon treatment with
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leading to this recently observed block in reverse transcription are
not yet clear.
On the other hand, interaction of viral accessory proteins
with cellular proteins may be a major factor influencing early
steps in the HIV life cycle. The viral protein Vpr, a constituent
of the nucleocapsid of the infecting virus particle, is required for
an efficient replication of the virus in monocytes and macro-
phages (Connor et al., 1995; Ayyavoo et al., 1997). This effect
is partially ascribed to its function to arrest cells in G2/M phase
of the cell cycle, which is thought to provide more favourable
conditions for enhanced HIV LTR driven gene expression.
Additional functions of Vpr include transactivation of the HIV
LTR prior to the action of Tat. HIV-1 Vpr has been shown to
transactivate LTR-directed expression through its interaction
with several proteins of cellular origin, including the gluco-
corticoid receptor (GR) (Thotala et al., 2004). In addition to
these functions, Vpr interacts with a number of transcription
factors, and co-factors, including the p300/CREB binding
protein and TFIIB (reviewed in: Kino and Pavlakis, 2004). Vpr
can act as a co-activator of GR on glucocorticoid responsive
promoters (Felzien et al., 1998; Kino et al., 2002), but availableFig. 1. Dexamethasone enhances HIV gene expression in naive PBMCs without stim
dexamethasone (Dex) 3 h postinfection as indicated or infected 24 h after PHA stimu
presence of viral capsid proteins byWestern blotting using a CA specific monoclonal a
of infected PBMCs left untreated (left panel) or treated with dexamethasone (right pane
and visualized with DTAF labeled secondary antibodies. (C) Detection of CA antigen
Bal (NL4-3 with the env of Bal). Cells were left untreated or treated with 1 µM dexame
content. (D) Cell cycle analysis. PBMCs were left untreated or treated with dexameth
analyzed by flow cytometry.data question the direct stimulatory effect of GR on the HIV
LTR and on HIV gene expression, since the HIV LTR does not
contain a bona fide GRE (Soudeyns et al., 1993). Although in
reporter assays Vpr was also shown to transactivate the HIV-1
LTR through the host GR pathway (Vanitharani et al., 2001). In
T cells, however activation of GR was even shown to inhibit the
HIV-LTR-driven gene expression (Kino et al., 2000; Mitra
et al., 1995). Alternatively, Vpr–GR complexes may rather
affect the regulation of cellular promoters, which may play a
significant role in changing the normal GR dependent gene
expression. This, for instance, can affect the regulation of
cytokine expression (Kino et al., 1999).
Recently, complex formation between Vpr, GR and poly
(ADP-ribose) polymerase-1 (PARP-1) has been identified
(Muthumani et al., 2006), which prevents nuclear translocation
of PARP-1. This results in a Vpr dependent suppression of the
growth promoting transcription factor NF-κB, and therefore
may lead to T-cell depletion and immunosupression observed in
HIV infected individuals. Thus Vpr can impair nuclear transport
of cellular regulatory proteins and thereby gains pleiotropic
functions in the complex regulatory network of the immune
system.ulating cell proliferation. (A) PBMCs were left either untreated or treated with
lation. After 3 days the cells were harvested and the cell lysates analyzed for the
ntibody. The position of the Gag precursor is indicated. (B) Immunofluorescence
l) at 3 h postinfection. Cells were fixed and stained with a mouse anti-p24 antibody
in cell lysates of PBMCs infected either with NL4-3/VSV-G pseudotypes or NL.
thasone. Amount of CA antigen was detected by ELISA and corrected for protein
asone as above. The DNAwas stained with propidium iodide and the cells were
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form (Bamberger et al., 1996), and Vpr has been shown to
promote nuclear transport of the preintegration complex
(reviewed in: Sherman and Greene, 2002), one can assume
that interaction between Vpr and GR can be central to early
steps in the HIV life cycle.
This assumption prompted us to investigate, whether
activation of GR in naive PBMCs might be a mechanism to
overcome the restriction in HIV replication in these cells. Our
results clearly show that activation of GR results in an increase
of HIV gene expression in a Vpr dependent manner, most likely
by promoting nuclear import of the preintegration complex
(PIC), which in turn results in an increase in the number of
provirus carrying cells.Fig. 2. Time dependence of dexamethasone addition on Gag expression levels in PB
cell lysates of PBMCs infected with NL4-3 pseudotypes at 72 h postinfection by E
The amounts of p24 antigen were corrected for protein contents. Standard Devi
transcripts was done by a semiquantitative nested PCRs from cellular DNA prepa
further details see Materials and methods). (C) Total cellular DNA was isolated fro
products was determined by real-time PCR. The data are means from two differe
(D) Gag expression (upper panel) and amount of proviral DNA (lower panels) fr
Proviral DNAwas detected by semiquantitative nested PCRs from two independent
see Materials and methods).Results
In naive PBMCs HIV-1 gene expression is substantially
increased upon ligand activation of GR
PBMCs were infected with the T-tropic HIV-1 strain NL4-3
pseudotyped with VSV-G to overcome any restriction to virus
entry. In accordance with the tropism of the NL4-3 strain, virus
replication was restricted to a single round of infection in these
cells. Efficacy of virus production was assayed by detection of
Gag protein expression by Western blot analysis in total cell
lysates at 3 days post infection. Consistent with previous obser-
vations Gag proteins were significantly less abundant in naive
PBMCs (Fig. 1A, lane 1) compared to PBMCs stimulated withMCs and enhancement of proviral integration. (A) Detection of CA antigen in
LISA. Dexamethasone was added at the indicated time points after infection.
ation is indicated by error bars. (B) Detection of proviral DNA and reverse
red 24 h after infection. Amplification of globin DNA served as controls (for
m cells treated as in (A). The presence of early and late reverse transcription
nt experiments and were corrected with the values obtained for globin DNA.
om the cells treated as in (A). Gag levels were detected by immunoblotting.
isolations of total cellular DNA prepared 24 h after infection (for further details
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could increase virus protein synthesis in naive PBMCs, we
added the GR ligand dexamethasone at concentrations of 1 μM
and 3 µM at 3 h after virus infection. As shown in Fig. 1A (lanes
2 and 3) the Gag protein levels in lysates of PBMCs treated
with the ligand were significantly increased. PHA-stimulated
PBMCs, which per se are permissive for virus replication,
showed prominent HIV-1 gene expression in the absence of the
ligand. The observed increase in virus protein synthesis in naive
PBMCs after GR ligand addition corresponded to an increase in
the number of Gag positive cells seen in immunofluorescence
(Fig. 1B). The same increase in the level of Gag protein was
obtained when cells were infected with the M-tropic virus strain
NL.Bal without the VSV glycoprotein (Fig. 1C), thus favouring
viral entry by fusion rather than by endocytosis (Aiken, 1997).
In order to demonstrate that activation of GR by addition of
ligand per se is not a signal for the cells to enter the cell cycle,
we analyzed the DNA content of untreated and dexamethasone
treated cells after 48 h by flow cytometry. As clearly shown, the
cell cycle profile of naive PBMCs did not change after ligand
addition, still showing an accumulation of the cells in the G1
phase of the cell cycle (Fig. 1D).
The stimulatory effect of the ligand is confined to an early
phase in infection and leads to an enhanced level of integrated
provirus
In order to determine at which step during virus replication
GR activation might be required, we added the ligand at
different time points after infection and analyzed the cells for
Gag expression. As shown in Fig. 2A, the stimulating effect of
dexamethasone was only found when the ligand was given at 3
to 7 h after infection.
Because the effect of the ligand proved to be confined to the
early phase of the infection cycle, we assumed that ligand
treatment could affect reverse transcription or provirus integra-
tion or both. In order to differentiate between these options, total
cellular DNA was isolated at 24 h after infection and used as
template for semiquantitative PCR analysis. The level of reverse
transcription was assayed by a nested semiquantitative PCRFig. 3. Knock-down of the glucocorticoid receptor impairs HIV-1 gene expression an
dexamethasone at 3 h after infection and analyzed for HIV specific gene expression a
lentiviral vectors expressing either a control (scrambled) shRNA (lanes 1) or shRNA
selection the cells were infected with HIV-1 strain NL 4-3 pseudotyped with VSV-G.
by Western blot. (C) Genomic DNA was assayed for integrated proviral DNA by ausing gag primers specific for late reverse transcription (see
Materials and methods). As shown in Fig. 2B, dexamethasone
treatment did not lead to an enhanced signal intensity of the
corresponding PCR product. However when we checked the
genomic DNA isolated 24 h after infection for integrated
proviral DNA by a nested semiquantitative PCR, using human
Alu and HIV LTR primers, the signal intensity of the specific
PCR product was significantly higher in the samples of ligand
treated cells compared to untreated cells (Fig. 2B). This sug-
gests that ligand treatment increases the number of provirus
carrying cells. However as mentioned before, it has been
suggested that resting T cells exhibit a block between early and
late reverse transcription. In order to exclude that ligand
addition overcomes this restriction, we analyzed early and late
reverse transcription by real-time PCR. Ligand addition had
only marginal effects on the levels of both early and late reverse
transcription, although late reverse transcription products were
also less abundant in unstimulated PBMCs (Fig. 2C). However,
the fact that especially early reverse transcription is not in-
fluenced by ligand addition is an indication that earlier stages of
the virus life cycle are unaffected by GR activation. Instead, our
data strongly suggest that a step occurring after reverse tran-
scription and prior to integration is affected. In order to
substantiate this finding, we analyzed both DNA and protein
lysates from cells treated with dexamethasone at different times
after infection (Fig. 2D). HIV protein expression (upper panel)
and proviral integration (lower panels) obtained maximal levels
when GR was activated 3 to 7 h after infection (Fig. 2D). Both
signals decreased when the ligand was added at later time points
indicating that preintegation complexes containing unintegrated
viral DNA are probably targeted for degradation. In summary,
our data suggest that treatment of cells with a GR ligand
overcomes a block in viral replication that exists after reverse
transcription and interferes with proviral integration.
Knock-down of GR in a permissive monocytic cell system
impairs Gag expression and provirus integration
Taken together our results suggested that activation of GR by
a ligand is crucial for an efficient virus replication in naived proviral integration in a monocytic cell line. (A) THP-1 cells were treated with
nd proviral integration. For the GR knock-down THP-1 cells were infected with
specific for the human glucocorticoid receptor (lanes 2). 6 days after puromycin
(B) 48 h after infection the cells were analyzed for GR and HIV Gag expression
nested semiquantitative PCR 24 h after infection.
Fig. 4. Subcellular localization of the glucocorticoid receptor in PBMCs after dexamethasone treatment or PHA stimulation. PBMCs were left untreated (A and B, left
panel) or treated with dexamethasone (B, middle panel) or stimulated with PHA (B, right panel). The cells were fixed and stained with rabbit anti-GR antibodies or a
mouse anti-vimentin monoclonal antibody as indicated and visualized with Alexa 488 and Alexa 555 labeled secondary antibodies. Cell nuclei were stained with
DRAQ5. Overlays are shown in the lower panel (B).
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GR in a permissive system should impair HIV gene expression.
Because silencing of GR takes 5 to 6 days after lentiviral trans-
duction with an shRNA coding virus, and PBMCs naturally
become permissive for HIV during this time in culture, we chose
a permissive monocytic cell line (THP-1) to study the effect of
GR knock-down on HIVreplication. In these cells GR activation
had no effect on the levels on HIV gene expression and proviral
integration (Fig. 3A). For the knock down the cells were
transduced with a control lentiviral vector or a vector expressing
shRNA specific for human GR and were selected for transgene
expression by puromycin resistance. After 6 days they were
challenged with HIV-1 strain NL4-3 pseudotyped with VSV-G.Fig. 5. Translocation of Vpr–GFP in PBMCs after dexamethasone treatment. PBMC
20 h they were left untreated (left and middle panel) or treated with dexamethasone
was studied at 20 min after dexamethasone addition (right panel).The results are shown in Fig. 3B and C. Western blot analysis
indicated a strong reduction in GR expression in transgenic cells
and a decrease in viral capsid protein expression, compared to
control cells transduced with a vector coding for a scrambled
shRNA (Fig. 3B). Accordingly, semiquantitative PCR using
genomic DNA from infected cells as templates showed lower
levels of integrated proviral DNA in GR-shRNA transduced
cells as in control cells (Fig. 3C). These data substantiate the
suggestion that GR can play a significant role specifically early
in the HIV life cycle by promoting provirus integration into the
host genome. Knock-down of the receptor resulted in a sig-
nificant reduction in the amount of integrated provirus leading to
reduced virus specific gene expression.s were transfected either with eGFP or with a Vpr–GFP expression vector. After
(right panel). Cell nuclei were stained with DRAQ5. Translocation of Vpr–GFP
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GR in naive but not in PHA-stimulated PBMCs
The viral regulatory protein Vpr plays a critical role early in
the HIV life cycle. Vpr is part of the incoming viral capsid and
becomes part of the preintegration complex (PIC), translocating
with PIC into the nucleus after reverse transcription (for a review
see: Sherman and Greene, 2002). During this process Vpr
associates with GR, suggesting that activated GR can promote
nuclear import of PIC (Heinzinger et al., 1994; Kino et al., 1999;
Sherman et al., 2000).
Thus we asked whether ligand treatment is required in
human naive PBMCs to promote nuclear transport of GR. In the
absence of hormone, GR was present in the cytoplasm (Figs. 4A
and B, left panel). After addition of the GR specific ligand
dexamethasone and a 10 min lag time, the receptor was released
from the cytoplasm and translocated into the nucleus (Fig. 4B,Fig. 6. Effect of Vpr deletion on Gag expression and provirus formation in PBMCs
infected either with WT virus or NL 4-3 ΔVpr. Dexamethasone (Dex) was added at
panel) from the cells treated as in (A). Gag levels were detected by immunoblotting.
PCRs from total cellular DNA prepared 24 h after infection (for further details see M
Gag expression in PHA-stimulated PBMCs. Cells were stimulated with PHA 24 h pr
analyzed 72 h after infection by immunoblotting using an anti-CA monoclonal antib
DNA isolated 24 h after infection from the same cells as in (C).middle panel). In contrast, in PHA-stimulated PBMCs, which
per se are permissive to HIV replication, GR was constitutively
present in the nucleus, independent of hormone stimulation
(Fig. 4B. right panel). The data indicate that ligand dependent
activation of GR is required in naive, but not in PHA-stimulated
PBMCs to shift the equilibrium in its subcellular localization
towards the nucleus.
Furthermore, we asked whether stimulation of PBMCs with a
GR ligand was also required for an efficient nuclear transloca-
tion of a transiently expressed Vpr. Naive PBMCs displayed a
strong cytoplasmic GFP fluorescence when transfected with a
plasmid expressing a fusion protein of Vpr and GFP (Fig. 5,
middle panel). Addition of the GR ligand dexamethasone 20 h
after transfection resulted in accumulation of the GFP signal of
the fusion protein first at the nuclear membrane and then it also
accumulated in the nucleus (Fig. 5 right panel). In contrast, eGFP
was also detected in the nucleus of transfected cells without GR. (A) Amount of CA antigen in the culture medium of cells 48 h postinfection
3 h after infection. (B) Gag expression (upper panel) and proviral DNA (lower
Reverse transcripts and proviral DNAwere detected by semiquantitative nested
aterials and methods). (C) Effect of Vpr deletion and dexamethasone addition on
ior to infection and dexamethasone was added 3 h postinfection and lysates were
ody. (D) Real-time PCR of early and late reverse transcription products of total
Fig. 7. Distinct subcellular distribution of the glucocorticoid receptor and
differential HIV-1 gene expression and proviral integration in rat glioma cells and
effect of dexamethasone addition. (A) The glioma cells (C6D8)were left untreated
(upper panel) or were treated with dexamethasone (lower panel). The
glucocorticoid receptor was stained with rabbit anti-GR antibodies and visualized
with FITC labeled secondary antibodies. (B) Western blot analysis of C6D8 cells
infected with HIV-1/VSV-G pseudotypes. Dexamethasone (1 µM) (Dex) was
added 3 h after infection. After 3 days the cells were harvested and the cell lysates
were analyzed by immunoblotting using an anti HIV-1CAantibody. The positions
of theGag precursor and p24 capsid (CA) are indicated. (C) Northern blot analysis
of total RNAwas done from the same cells as analyzed in (B). The probe used for
detection of virus specific RNA allowed the detection of all three classes of HIV
specific RNAs (seeMaterials andmethods). Positions of HIV-1 specific RNAs are
shown. (D) PCR analysis of integrated proviral HIV-1 DNA in the C6D8 cells
infected with HIV-1/VSV-G pseudotypes. Cells were left untreated or treated with
dexamethasone as above. Genomic DNA was prepared 24 h after infection and
assayed for integrated proviral DNA by semiquantitative nested PCR (see
Materials and methods for details). In lanes 1 and 2 DNA from infected cells and
in lane 3 DNA from uninfected cells was used as templates. Amplification of rat
β-globin sequences served as controls (lower panel).
79K. Wiegers et al. / Virology 375 (2008) 73–84activation by ligand (Fig. 5, left panel). These data indicate that
transiently expressed Vpr and endogenous GR behave in the
same manner with respect to their subcellular localization, and
both require the presence of a GR ligand for an efficient nuclear
transport. This result is consistent with the notion that the virion
associated non-structural protein Vpr associates with GR in the
cytoplasm of infected cells (Refaeli et al., 1995; Sherman et al.,
2000).
Vpr and activation of GR by ligand are both required to
promote infection of naive PBMCs
In the next experiments we asked whether in addition to the
ligand dependent activation of GR a functional Vpr is also
required for the initiation of a productive infection in non-
permissive, naive PBMCs. However, when naive PBMCs were
infected with the isogenic mutant lacking Vpr (Vazquez et al.
2005), Gag expression was even further reduced as compared to
the infection with wild type virus (Figs. 6A and B, upper panel,
lanes 1 and 3). Furthermore, ligand treatment could not
overcome this restriction (Figs. 6A and B, upper panel, lanes 2
and 4). By semiquantitative PCR analysis using human Alu and
HIV LTR primers, we could show that in this case integrated
proviral DNA is hardly detectable (Fig. 6B, lower panel, lane 3)
and not increased after receptor activation, in contrast to WT
virus infected cells (Fig. 6B, lower panel lanes 2 and 4). Thus
both, Vpr and ligand activation of the receptor are required for an
efficient initiation of a productive infection in these cells. In
contrast, Gag protein levels are reduced after receptor activation
in PHA-stimulated PBMCs (Fig. 6C, lanes 3 and 4) and the
differences between withWT virus and Vpr-deficient virus were
no longer apparent (Fig. 6C, lanes 3 to 6). Note that also the
levels of reverse transcription remained unaffected by the addi-
tion of ligand, whether stimulated PBMCs were infected either
with WT virus or the mutant lacking Vpr (Fig. 6D).
Rat cells with a constitutive cytoplasmic localization of GR
behave identical to PBMCs
Our data suggest that in naive PBMCs the efficacy of virus
production is dependent on an activation step by a GR ligand
prior to integration. Likely, this activation step is important to
promote transport of GR in a complex with PIC into the
nucleus. To substantiate this relation we included in our studies
a rat glioma cell line (C6D8), completely unrelated to PBMCs,
but showing the same constitutive cytoplasmic GR localization
as naive PBMCs. In the absence of hormone, the cells predom-
inantly harbored GR in the cytoplasm (Fig. 7A, upper panel).
Addition of dexamethasone induced a nuclear translocation of
the receptor within a short time range (Fig. 7A, lower panel).
Based on this observation, we examined whether the ligand
induced translocation of GR in these cell had also an effect on
the efficacy of HIV-1 gene expression.
Cells were also infected with VSV-G pseudotyped HIV-1 to
overcome the restriction in HIV-1 entry in these rat cells. Viral
gene expression was also monitored by detection of capsid
protein expression by Western blot analysis. Total cell lysateswere also analyzed at 3 days postinfection. In order to exclude
another downstream block in the viral replication cycle in C6D8
cells, e.g. impaired maturation of the virus at the plasma
membrane, as shown for other rodent cell systems (Bieniasz and
Cullen, 2000); (Mariani et al., 2000), we also analyzed the
infected cells by thin section electron microscopy (EM). The
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particles with typical lentivirus cone shaped cores inside the
virus shells. However, in untreated C6D8 cells virus particles
were only rarely detected (not shown). This result precludes the
presence of a specific assembly block for HIV-1 in C6D8 cells.
To monitor the effect of GR activation, we added dex-
amethasone (1 µM) to infected C6D8 cells at 3 h postinfection.
Addition of the GR ligand to these nonpermissive cells increased
the levels of both, total virus specific RNA and capsid proteins
dramatically (Fig. 7B and C lane 2).
In order to determine if provirus integration was affected in
the nonpermissive cells we analyzed the genomic DNA for the
amounts of integrated provirus 24 h after infection using a nested
semiquantitative PCR (Keppler et al., 2002). The results show
that untreated cells contained far less copies of proviral DNA
than cells after receptor activation (Fig. 7D, lanes 1 and 2). This
is a strong indication that the block in these cells, which is
overcome by activation of GR, likely exists before integration as
seen in naive PBMCs. Additional support for this notion was
obtained from Tat transactivation experiments, where in these rat
cells no defects in the expression of appropriate reporter
constructs were detected (not shown).
Furthermore, infection with the Vpr deletion mutant did not
rescue Gag expression, rather even further reduced levels were
obtained, similar to the results seen in naive PBMCs (data not
shown). Thus both, Vpr and receptor activation by the ligand
are required for an efficient initiation of a productive infection
in these cell types.
Discussion
Our studies show that activation of the glucocorticoid
receptor by the ligand dexamethasone overcomes restriction in
HIV-1 replication in freshly isolated PBMCs. The finding
underscores the critical role of this nuclear receptor in the HIV-1
life cycle. GR has been discussed to promote HIV-1 replication
by stimulating provirus transcription either directly by binding
to a putative GR responsive element in the long terminal repeat
(Furth et al., 1990; Ghosh, 1992; Mitra et al., 1995) or indirectly
by enhancing the effects of cytokines and transcription factors
(Kinter et al., 2001). A major basis of this stimulatory effect is
the physical interaction of GR with the accessory viral protein
Vpr (Sherman et al., 2000). Vpr has been described also to
interact with other transcription proteins, namely Sp1 (Wang
et al., 1995), TFIIB (Agostini et al., 1999) and to recruit p300/
CBP (Felzien et al., 1998). Thus Vpr can act as a co-activator of
the glucocorticoid receptor, providing a backbone for the for-
mation of a large transcriptional complex to promote provirus
transcription (Kino et al., 1999).
Although, we cannot exclude that activation of GR in PBMCs
to some extent also enhances transcription of the HIV-1 provirus,
our data rather suggest that activated GR influences an early step
in the HIV-1 life cycle, prior to provirus transcription. As shown
by a nested semiquantitative PCR using primers specific for late
reverse transcription products, the signal was identical whether
or not the cells had been treated with dexamethasone. Further-
more, real-time PCR indicated that ligand treatment had noinfluence on the level of early reverse transcription products, but
increased significantly the PCR signal identifying viral genomes
integrated into the host genome. It suggests that ligand treatment
does not affect virus entry and reverse transcription, but in-
creases the number of provirus copies. The effect of ligand
treatment was confined to a time period early after infection of
PBMCs, further substantiating that the effect of GR activation is
not based on an enhanced provirus transcription. Our data
confirm the statement of others that HIV-1 replication in PBMCs
is blocked prior to integration (Sonza et al., 1996), but we
suggest that a block exists not before but after the step of reverse
transcription. Identical results were obtained when the cells were
infected with the M-tropic NL4-3 derivative NL.Bal (Mariani
et al., 2001), indicating that our finding does not reflect an
artificial response specific for VSV-pseudotyped HIV-1.
The increase in provirus copies seen upon ligand treatment was
only observed when PBMCs were infected with virus containing
a functional Vpr. It substantiates the critical role of Vpr in nuclear
translocation of PIC. Vpr is packaged in the progeny virions at
high copy numbers (Cohen et al., 1990) and it was shown to be
indispensable for nuclear localization of viral nucleic acids in
non-dividing cells (Heinzinger et al., 1994). Vpr was found to
dock at the nuclear envelope and to interact with importin-α
(Vodicka et al., 1998; Fouchier et al., 1998; Nitahara-Kasahara et
al., 2007), suggesting that Vpr interacts with the cellular import
machinery to facilitate translocation of PIC into the nucleus. Our
data extend these observations showing that efficient provirus
formation in PBMCs depends not only on the fact that the virus
contains a functional Vpr but also that GR is activated by a ligand.
Conversely, ligand treatment was inefficient in infections with a
virus lacking Vpr. We assume that nuclear translocation of PIC in
PBMCs utilizes pathways regulating nuclear import of GR.
Consistent with this notion, PBMCs not treated with dexametha-
sone harboured the receptor in the cytoplasm,whereas in presence
of the ligand the receptor accumulated in the nucleus. This not
necessarily implies that Vpr-GR interaction is not functional in
the absence of a ligand. It was well demonstrated that binding of
PARP-1 to Vpr requiring complex formation with GR takes place
in the absence of a GR ligand (Muthumani et al., 2006). This step
impairs nuclear entry of PARP-1 and suppresses NF-κB and
thereby contributes to the immunosuppressive action of the virus.
Thus, interaction betweenVpr andGR can be a gain of function in
a ligand dependent and a ligand independent manner, both of
which affect the subcellular localization of viral and cellular
constituents. In a combined action these mechanisms could
significantly enhance virus production.
Our data support suggestions of previous reports that a strong
functional cooperation between Vpr and GR in regulating
nucleo-cytoplasmic trafficking in the HIV-1 life cycle is required.
Treatment of PBMCs with dexamethasone only led to an
efficient provirus integration when the ligand was given within a
time period shortly after infection. It suggests that the ligand
dependent effect competes with processes withdrawing incom-
ing cores and viral nucleic acid from the infection cycle. Zhou
et al. (2005) have shown that in resting CD4+ Tcells, virus decay
is due to infection-induced apoptosis and intracellular degrada-
tion before and after the completion of reverse transcription. The
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transcripts in these cells was about 24 h. In addition to the
degradation pathway, HIV infection itself could trigger processes
that may change the intracellular environment and signalling
pathways in a way, that the cells become insensitive to the action
of GR ligands. Further studies monitoring the fate of incoming
virus particles in relation to the functional status of GR could help
to explain these results.
Whereas freshly isolated PBMCs showed a clear correlation
between GR activation, extent of provirus integration, and the
subsequent expression levels of newly synthesized viral capsid
proteins, all of which demanded the presence of a functional
Vpr, this correlation was lost in cells which had been stimulated
with the mitogen PHA for 24 h. This corresponds to the notion
that resistance to the establishment of productive infection by
HIV-1 in freshly isolated PBMCS is abolished when the
monocytes are stimulated to mature and differentiate (Fear et al.,
1998; Sonza et al., 1996; Kimata et al., 1998; Mwaengo and
Novembre, 1998). As shown here, PHA-stimulated PBMCs
efficiently produced viral capsid proteins at equal levels
whether or not they were incubated with the GR ligand
dexamethasone, even when the virus lacked a functional Vpr.
The factors determining this dramatic change in sensitivity to
infection with HIV-1 are not known. Consequences of mitogen
stimulation are complex, including activation of proliferation and
changes in cytokine expression (Poindexter et al., 2005). These
changes may also apply for the relief of the recently described
restriction in resting T cells caused by APOBEC3G (Chiu et al.,
2005). Possibly, ligand enhanced provirus integration requiring
Vpr and GR is a pathway adjusted specifically to environmental
conditions in peripheral mononuclear blood cells, normally the
first cells to come in contact with the virus during natural
infection. They can contribute to the establishment of virus
reservoirs, crucial to subsequent spread to lymphoid organs and
T-helper lymphocytes. Further studies are necessary to determine
if the effect described here is specific for a certain subpopulation
of PBMCs. But studies on the mechanisms regulating the
interaction between Vpr and GR in HIV-1 infection of PBMCs
are hampered by the heterogeneity of this cell fraction and
moreover by the fact that these cells gradually change their
phenotype during cultivation in vitro. These changes made it
impossible for us to study the effect of downregulation of GR in
freshly isolated PBMCs, as this requires the maintenance of the
cultures at a prolonged time period at various growth conditions.
In this respect it was of interest to find that a subclone of the rat C6
glioma cell line revealed the same phenotype as freshly isolated
PBMCs, namely the requirement of GR activation by ligand for
efficient virus production. This offers the opportunity to gain
basic insights into this pathway by using this homogenous cell
population as an experimental system.
Materials and methods
Cells, transfections, and infections
HeLa P4 cells (Clavel and Charneau, 1994), stably ex-
pressing the CCR5 coreceptor (HeLa P4/CCR5) were kindlyprovided by M. Alizon (Institut Cochin de Genetique
Moleculaire, Paris, France). THP-1 cells and C6 rat glioma
cells were obtained from the American Type Culture Col-
lection (ATCC CCL 107; Rockville, MD, USA). The subclone
C6D8 was isolated from microtiter plates by limiting dilution
(Roser et al., 1991). HeLa P4 cells, 293T cells and C6D8 cells
were maintained in Dulbecco's modified minimal Eagle's
medium supplemented with 10% heat-inactivated fetal calf
serum, 100 U of penicillin per ml, 100 µg of streptomycin per
ml, and 2 mM glutamine. PBMCs from normal HIV-1 se-
ronegative donors were isolated by Ficoll-Hypaque density
centrifugation. The cells were washed twice in RPMI 1640 and
resuspended to give 1×106 cells/ml in RPMI 1640 containing
10% fetal calf serum (FCS) and incubated overnight at 37 °C.
Non adherent cells were collected and washed once with RPMI
1640 10% FCS. PHA stimulation (10 µg/ml) was done 24 h
prior to infection. For cell cycle analysis the CycleTest kit from
Becton and Dickinson, Germany was used according to the
manufacturer's protocol and the cells were analyzed by flow
cytometry.
HIV-1 wild type virus or HIV-1/VSV-G pseudotyped virus
were produced in HeLa P4 cells by Lipofectamine (Invitrogen,
Germany) aided transfection in 10 cm dishes with 15 µg of HIV-
1 pNL4-3 DNA (Adachi et al., 1986) or 15 µg pNL4-3 DNA and
5 µg of a VSV-G expression vector, respectively. This latter
plasmid and the plasmid NL.Bal (NL4-3 with the env of Bal)
(Mariani et al., 2001) were kindly provided by N. Landau
(Salk Institute, San Diego, USA). Pseudotyped virus lacking a
functional Vpr was produced by cotransfection of pNL4-3ΔVpr
(Vazquez et al., 2005) which was kindly provided by U.
Schubert (University of Erlangen, Germany) and the VSV-G
expression plasmid. Virus stocks were analyzed by p24
ELISA and stored at −80 °C. PBMCs (1.5 to 2.0×106) were
infected with 500 ng of p24 antigen and incubated at 37 °C for
3 h. After washing twice with PBS they were resuspended
in RPMI 1640 containing 10% FCS and incubated further at
37 °C.
For infection of the subclone C6D8 of the C6 Glioma cell
line, 2×106 cells were seeded in 10 cm Petri dishes and
cultivated overnight at 37 °C. The next day the culture medium
was removed and the virus (400 to 500 ng of p24 antigen) was
added to the plates. After 3 h the virus was removed and after
washing the dishes twice with PBS fresh culture medium was
added. Dexamethasone was added 3 h postinfection at the con-
centration indicated. For transfection of unstimulated PBMCs
with eGFP and Vpr–GFP (McDonald et al., 2002) expression
vectors, the nucleofector kit (Amaxa, Germany) according to the
manufacturer's protocol was used. Briefly, 2×106 PBMCs
isolated as above were transfected with 1 µg of plasmid DNA of
either eGFP or Vpr–GFP. After 20 h cells were left untreated or
treated with dexamethasone (1 µM) and analyzed by confocal
microscopy.
The lentiviral control vector DNA (SHC002) containing a
scrambled sequence and the vector DNA for silencing human
GR (SHDNAC-TRC0000019319) were obtained from Sigma,
Germany. Lentiviral particles were produced in 293T cells by
cotransfection of 3 µg vector DNA, 3 µg packaging construct
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VSV-G expression construct. Viral particles were harvested after
48 h and stored at−80 °C. For silencing of GR, THP-1 cells were
infected with 500 ng (p24) lentiviral vector and selected for
stably transduced cells with puromycin. After 6 days the cells
were challenged with HIV/VSV-G pseudotypes. Genomic DNA
was prepared 24 h after infection and cell lysates were prepared
after 48 h for protein analysis.
Analysis of expression products
HIV antigens were analyzed using a quantitative ELISA
detecting the viral CA protein (Konvalinka et al., 1995). For
Western Blot analysis, cell extracts were separated on 12.5%
SDS-polyacrylamide gels and proteins were transferred to
nitrocellulose membranes (Schleicher & Schuell, Dassel,
Germany) by electroblotting. Membranes were blocked with
10% low fat dry milk in PBS for 1 h and subsequently reacted
with a monoclonal antibody (183) against HIV-1 CA obtained
from the NIH AIDS Research and Reference Reagent Program.
The antibody was purified from cell culture supernatant by
protein A affinity chromatography andwas concentrated to about
8 to 10mg/ml. The antibodywas diluted 1:2000 to 1:4000 in PBS
containing 5% low fat drymilk, 0.05%Tween 20. Incubationwas
carried out overnight at room temperature with shaking. After
washing three times with PBS containing 0.05% Tween 20,
peroxidase-conjugated anti-rabbit antibodies (Dianova, Ger-
many) were used as secondary antibodies and incubated for 2 h
at room temperature. Immune complexes were visualized using
enhanced chemiluminescence (ECL; Amersham, Germany)
according to the manufacturer's instructions.
Northern blot analysis
Total RNA was isolated from 5×106 to 1×107 cells using
trizol reagent (Invitrogen, Germany) as suggested by the
manufacturer. 10 to 20 µg RNAwere loaded onto formaldehyde
containing 1.2% agarose gels. The RNA was transferred to
Hybondmembranes (Amersham,Germany) by capillary transfer.
32P-labeled probes were made by random priming using the
NcoI/XhoI fragment from pNL4-3, which allowed detection of
all three classes of HIV-1 specific RNAs.
Detection of integrated proviral DNA
A semiquantitative nested PCR for the specific amplification of
HIV-1 proviral DNA integrated into the human or rat genome was
used. For PBMCs a human Alu primer was used (5′-CTCAC-
GCCTGTAATCC-CAGCA-3′) and for the rat genome an
oligonucleotide primer BC1-A (5′-GGATTTAGCTCAGTGG-
TAGA-3′) from a consensus sequence that is highly abundant in
the rat genome was used (Chun et al., 1997). Genomic DNAwas
extracted from infected cells 24 h after infection using DNAzol
(Invitrogen, Germany). The PCR reactions were done as described
previously (Keppler et al., 2002). Briefly, the first PCR amplifica-
tion was done with the HIV-1 LTR primer (5′-AGGCAAGCTT-
TATTGAGGCTTAAGC-3′) and the BC1-A primer or the humanAlu primer. The reaction was run with the following program:
(a) 3 min at 94 °C, (b) 30 cycles of 30 s at 94 °C, 30 s at 57 °C, and
4 min at 72 °C, and (c) 10 min at 72 °C. A second nested PCR
amplification, which allows amplification of a 357-basepair LTR
fragment, was performed by using 1 µl of the first reaction with
internal HIV-1 LTR primers NI-2 5 and NI-2 5, (5′-CACACA-
CAAGGCTACTTCCCT-3′), and NI-2 3, (5′-GCCACTCCCCA-
GTCCCGCCC-3′(Chun et al., 1997). This second PCR was
performed using the same PCR conditions as for the first one,
except that the annealing temperature was raised to 60 °C, the
extension time was 1 min, and amplification was run for 25 cycles.
In control reactions fragments of the rat β-globin gene using the
primer pair (5′-TGACTCGCAACCTCAGGAA-3′and 5′-GGAT-
CCACATGCAGCTTG-3′) and of the human β-globin gene using
the primer pair (5′-CGAATGATTGCATCAGTGTGGAAGTC-3′
and 5′-GCAGAATGGTAGCTGGATTGTAGC-3′) were ampli-
fied. PCRproductswere analyzed by ethidiumbromide/agarose gel
electrophoresis.
Analysis of reverse transcription
Reverse transcribed products were detected by a nested PCR
targeted to the Gag region. For the first PCR the following primers
were used: Nts 1330–1351 5′-CCACAAGATTTAAATACCAT-
GC-3′ and Nts 1819–1840 5′-GACATGCTGTCATCATTTCT-
TC-3′. The nested PCR was done with the following primer pair:
5′-CCATCAATGAGGAAGCTGCAG-3′, 5′-GGTTCCTTTGG-
TCCTTGTCTTA-3′ representing Nts 1400–1420 and 1641–
1664, respectively. Both reactions were run with the same
protocol, except that for the nested PCR the cycle number was
increased from 14 to 29. (a) 3 min at 95 °C, (b) 14 cycles of 30 s at
95 °C, 30 s at 56 °C, and 4 min at 72 °C, and (c) 10 min at 72 °C .
Real-time PCR quantification of reverse transcripts
Total DNAwas prepared at the 24 h postinfection. Early and
late HIV-1 reverse transcription products were quantified using
specific primer and probe combinations (Chiu et al., 2005).
Reaction mixtures (10 µl) contained Platinum PCR MasterMix
(Invitrogen), 300 nM forward primers, 900 nM reverse primers
and 200 nMprobe and 1 µl of total DNA. PCRwas performed for
3 min at 95 °C followed by 40 cycles of 15 s at 95 °C, and 30 s at
60 °C using an ABI 7500 (Applied Biosystems). Detection of
early reverse transcripts was done with primers of R/U5 region
(forward: 5′-GGCTAACTAGGGAACCCACTGC-3′, reverse:
5′-AACAGACGGGCACACACTACT-3′, probe: 5′-(6~FAM)-
TAAGCCTCAATAAAGCTTGCCTTGAGTGCTC-(BHQ1a)-
3′; and of late reverse transcripts with primers of U5/Gag region
(forward: 5′-AGATCCCTCAGACCCTTTTAGTCA-3′, reverse:
5′-CTTTCGCTTTCAAGTCCCTGTT-3′, probe: 5′-(6~FAM)-
TGGAAAATCTCTAGCAGTGGCGCCC-(BHQ1a)-3′. Each
sample was tested in triplicates, and the results were normal-
ized using amplification of the same genomic DNA with
human β-globinprimers (HBG-forward: 5′-CTTAATGCCTTAA-
CATTGTGTATAA-3′, HBG-reverse: 5′-GAATATGCAAA-
TAAGCACACATATAT-3′, HBG-probe: 5′-(6~FAM)-
ACTTTACACAGTCTGCCTAGTACATTAC-TAMRA-3′).
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Infected PBMCs were washed once with PBS and fixed for
10 min in −20 °C methanol/acetone. After rehydration in PBS,
the cells were incubated with a mouse monoclonal anti-CA
antibody followed by DTAF labeled goat anti-mouse antibodies
(Dianova, Germany). C6D8 cells were washed once with PBS
and fixed for 10 min in −20 °C methanol/acetone blocked with
2% normal goat serum, incubated with rabbit anti-GR
antibodies, followed by FITC labeled goat anti-rabbit antibodies
(Dianova, Germany). Uninfected PBMCs were fixed with
acetone (−20 °C) blocked with 2% normal donkey serum and
labelled with monoclonal mouse antibodies to vimentin (V9,
Boehringer, Germany) and rabbit antibodies to human GR (E20,
Santa Cruz, U.S.A.). Donkey anti-mouse Alexa 488 and donkey
anti-rabbit Alexa 555 (Molecular Probes, USA) were used as
secondary antibodies. DNAwas stained with DRAQ 5. Optical
sections were produced with a Zeiss Meta Confocal Microscope
(Zeiss, Germany). Life images of transfected PBMCs were also
obtained with this microscope.
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